Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AM E3
- Development stage
- Unknown
- Lead developer
- IRBM
- Modality
- Antibody-Based Therapeutics
01
Overview
AM E3: sourced facts only. name: "AM E3, a fully human α-CRLF2 monoclonal antibody with single-digit nanomolar affinity for the target (5.9 ± 1.0 nM), was identified leveraging our proprietary phage display platform." [DOI:10.1158/1538-7445.am2025-4773]; target: "AM E3, a fully human α-CRLF2 monoclonal antibody with single-digit nanomolar affinity for the target (5.9 ± 1.0 nM), was identified leveraging our proprietary phage display platform." [DOI:10.1158/1538-7445.am2025-4773]; developer: "IRBM S.p.A., Pomezia, Italy." [DOI:10.1158/1538-7445.am2025-4773]; modality: "AM E3, a fully human α-CRLF2 monoclonal antibody" [DOI:10.1158/1538-7445.am2025-4773]
02
Targets
TSLPR (TSLP receptor)
Beyond the preview
Go deeper on AM E3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AM E3.